1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score: From the MASCOT registry.

ABSTRACT:

Background

The COMBO stent is a biodegradable-polymer sirolimus-eluting stent with endothelial progenitor cell capture technology for faster endothelialization.

Objective

We analyzed COMBO stent outcomes in relation to bleeding risk using the PARIS bleeding score.

Methods

MASCOT was an international registry of all-comers undergoing attempted COMBO stent implantation. We stratified patients as low bleeding-risk (LBR) for PARIS score ≤ 3 and intermediate-to-high (IHBR) for score > 3 based on baseline age, body mass index, anemia, current smoking, chronic kidney disease and need for triple therapy. Primary endpoint was 1-year target lesion failure (TLF), composite of cardiac death, myocardial infarction (MI) not clearly attributed to a non-target vessel or clinically-dr

SUBMITTER: Chandrasekhar J 

PROVIDER: S-EPMC7486438 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature